We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA GUIDANCE: AWARENESS PLANS MUST BE DISTINCT
FDA GUIDANCE: AWARENESS PLANS MUST BE DISTINCT
February 6, 2004
General disease awareness communications disseminated by drugmakers must be perceptually distinct from promotions of specific drugs or the awareness information will be subject to FDA rules governing promotional labeling and advertising, the agency said in a draft guidance last week.